| Schedule of Segment Reporting Information, by Segment |
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2025 | | 2024 | | 2025 | | 2024 | | Total revenues | $ | 81,504 | | | $ | 30,858 | | | $ | 147,350 | | | $ | 80,427 | | Less: | | | | | | | | | Cost of sales | 6,929 | | | 3,278 | | | 12,780 | | | 6,346 | | Topical roflumilast program costs | 2,827 | | | 2,931 | | | 4,273 | | | 6,519 | | Topical JAK inhibitor program costs | 343 | | | 595 | | | 719 | | | 1,262 | | Other early-stage programs costs | 1,695 | | | 1,835 | | | 3,690 | | | 5,968 | | | Research and development compensation and personnel-related expenses | 9,779 | | | 9,362 | | | 19,417 | | | 19,740 | | | Selling, general and administrative expenses | 69,033 | | | 58,049 | | | 132,917 | | | 112,720 | | Other segment expenses(1) | 5,509 | | | 4,885 | | | 12,694 | | | 9,571 | | | Total operating expenses | 96,115 | | | 80,935 | | | 186,490 | | | 162,126 | | | Operating loss | (14,611) | | | (50,077) | | | (39,140) | | | (81,699) | | | | | | | | | | | Other income, net | 2,096 | | | 5,229 | | | 4,826 | | | 9,273 | | | Interest expense | (3,029) | | | (7,484) | | | (6,011) | | | (14,964) | | | Provision for income taxes | 342 | | | — | | | 621 | | | 324 | | | Segment and consolidated net loss | $ | (15,886) | | | $ | (52,332) | | | $ | (40,946) | | | $ | (87,714) | |
|